Neoadjuvant therapy with Docetaxel (TAX) and Cisplatin (CIS) in patients (pts) with non-small cell lung cancer (NSCLC), stage IIIA, N2 is highly active with few toxicities

Abstract
No abstract available

This publication has 0 references indexed in Scilit: